Watchdog Accuses Drug Cos. Of Illegal Market Sharing

Law360, London (October 3, 2019, 3:30 PM BST) -- Britain’s antitrust regulator opened a probe Thursday into whether three pharmaceutical companies signed an illegal agreement on the supply of a drug, which it said led to a “significant price hike” for the medication.

The Competition and Markets Authority said it has provisionally found that South Africa’s Aspen Pharmacare Holdings Ltd. unlawfully agreed to pay Amilco, a British pharmaceutical consultancy, and Dutch manufacturer Tiofarma to stay out of the U.K. market for fludrocortisone acetate tablets, used to treat diseases of the adrenal gland.

Aspen admitted in August that it had taken part in anticompetitive practices but the British and Dutch companies...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS